Historical Valuation
TherapeuticsMD Inc (TXMD) is now in the Fair zone, suggesting that its current forward PS ratio of 2.08 is considered Fairly compared with the five-year average of 0.03. The fair price of TherapeuticsMD Inc (TXMD) is between 1.98 to 2.49 according to relative valuation methord.
Relative Value
Fair Zone
1.98-2.49
Current Price：2.06
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
TherapeuticsMD Inc (TXMD) has a current Price-to-Book (P/B) ratio of 0.70. Compared to its 3-year average P/B ratio of 0.81 , the current P/B ratio is approximately -14.46% higher. Relative to its 5-year average P/B ratio of -3.14, the current P/B ratio is about -122.20% higher. TherapeuticsMD Inc (TXMD) has a Forward Free Cash Flow (FCF) yield of approximately 10.83%. Compared to its 3-year average FCF yield of -106.91%, the current FCF yield is approximately -110.13% lower. Relative to its 5-year average FCF yield of -83.05% , the current FCF yield is about -113.04% lower.
P/B
Median3y
0.81
Median5y
-3.14
FCF Yield
Median3y
-106.91
Median5y
-83.05
Competitors Valuation Multiple
AI Analysis for TXMD
The average P/S ratio for TXMD competitors is 4.54, providing a benchmark for relative valuation. TherapeuticsMD Inc Corp (TXMD.O) exhibits a P/S ratio of 2.08, which is -54.29% above the industry average. Given its robust revenue growth of 43.33%, this premium appears sustainable.
Performance Decomposition
AI Analysis for TXMD
1Y
3Y
5Y
Market capitalization of TXMD increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TXMD in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TXMD currently overvalued or undervalued?
TherapeuticsMD Inc (TXMD) is now in the Fair zone, suggesting that its current forward PS ratio of 2.08 is considered Fairly compared with the five-year average of 0.03. The fair price of TherapeuticsMD Inc (TXMD) is between 1.98 to 2.49 according to relative valuation methord.
What is TherapeuticsMD Inc (TXMD) fair value?
TXMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of TherapeuticsMD Inc (TXMD) is between 1.98 to 2.49 according to relative valuation methord.
How does TXMD's valuation metrics compare to the industry average?
The average P/S ratio for TXMD's competitors is 4.54, providing a benchmark for relative valuation. TherapeuticsMD Inc Corp (TXMD) exhibits a P/S ratio of 2.08, which is -54.29% above the industry average. Given its robust revenue growth of 43.33%, this premium appears sustainable.
What is the current P/B ratio for TherapeuticsMD Inc (TXMD) as of Jan 09 2026?
As of Jan 09 2026, TherapeuticsMD Inc (TXMD) has a P/B ratio of 0.70. This indicates that the market values TXMD at 0.70 times its book value.
What is the current FCF Yield for TherapeuticsMD Inc (TXMD) as of Jan 09 2026?
As of Jan 09 2026, TherapeuticsMD Inc (TXMD) has a FCF Yield of 10.83%. This means that for every dollar of TherapeuticsMD Inc’s market capitalization, the company generates 10.83 cents in free cash flow.
What is the current Forward P/E ratio for TherapeuticsMD Inc (TXMD) as of Jan 09 2026?
As of Jan 09 2026, TherapeuticsMD Inc (TXMD) has a Forward P/E ratio of 10.31. This means the market is willing to pay $10.31 for every dollar of TherapeuticsMD Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for TherapeuticsMD Inc (TXMD) as of Jan 09 2026?
As of Jan 09 2026, TherapeuticsMD Inc (TXMD) has a Forward P/S ratio of 2.08. This means the market is valuing TXMD at $2.08 for every dollar of expected revenue over the next 12 months.